Guidelines for collecting data on retail drug prices in Europe [Recurso eletrónico] : issues and challenges / European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
Autor institucional: EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTIONIdioma: Inglês.Publicação: Luxembourg : Publications Office of the European Union, 2010Descrição física: 1 CD-ROM; 12 cmColeção: EMCDDA Manuals; 5ISBN: 9789291684137Assunto: 1233 | 238858 | 343871 | 322094 | 343238 | 321724 | 326972Resumo: Acknowledgements. Preface. Chapter 1: Introduction. Why collect data on (retail) drug prices? European and other international data collection systems on drug prices. Methods of collecting retail drug prices data in Europe and beyond. Why the present guidelines? Chapter 2: General data collection issues. Definition — retail drug prices. Sampling retail drug prices. Geographical coverage. Sampling over time. Factors influencing retail price observations. Determinants of drug markets. Characteristics of the retail drug markets. Products and purchases. Variables to record for each transaction. Legal issues related to data collection. Chapter 3: Principal methods of data collection in Europe. Overview of the principal methods currently in use in Europe. Covert drug purchases (by law enforcement agencies): test purchases. Objectives. Details of the method. Strengths and weaknesses. An example — National Covert Drug Purchase Database, United Kingdom. Informants run by law enforcement agencies. Objectives. Details of the method. Strengths and weaknesses. Interrogation of arrestees. Objectives. Details of the method. Strengths and weaknesses. Overt drug purchases (purchases by non-law enforcement agents). Objectives. Details of the method. Strengths and weaknesses. An example — SINTES information system, France. Surveys of drug users. Objectives. Details of the method. Strengths and weaknesses. An example — Survey ENa-CAARUD, France. An example — The Oslo study, Norway. An example — The Antenna monitoring scheme, The Netherlands. Interviews with key experts. Objectives. Details of the method. Strengths and weaknesses. An example — Project TREND, France. An example — Central Bureau of Investigation survey, Poland. Other methods. Eavesdropping. Documentation seized by law enforcement agencies. General population surveys. Ethnographic observation. Chapter 4: General data management, reporting and analysis issues. Study protocol. Products. Selecting transactions from the retail market. Dealing with non-standardised units. Data cleaning and construction of the data matrix. Construction of the data matrix. Validation procedures. Standard descriptive measures. Reporting — from local to national. Analysis at national level. Feedback to data providers. Publication. Cross-country comparative analysis. Glossary. Bibliography. Annexes. Annex 1: EMCDDA Standard Table. Annex 2: Metropolitan Police Service covert drug purchase database form. Annex 3: Notice 10-06 item 2 of the Metropolitan Police Service. Annex 4: Statistics and indicators: examples of calculation.| Item type | Current location | Call number | Copy number | Status | Date due | Barcode |
|---|---|---|---|---|---|---|
| Monografias | Biblioteca da Polícia Judiciária | PJCD143 (Browse shelf) | PJCD143 | Available | PJ1CD143_33 |
Ficheiro de 1,54 Mb em formato pdf (138 p.). Também disponível em: https://www.emcdda.europa.eu/attachements.cfm/att_101278_EN_EMCDDA-Manual5_Retail%20prices.pdf.Acedido a 15 de Abril de 2011.
Acknowledgements. Preface. Chapter 1: Introduction. Why collect data on (retail) drug prices? European and other international data collection systems on drug prices. Methods of collecting retail drug prices data in Europe and beyond. Why the present guidelines? Chapter 2: General data collection issues. Definition — retail drug prices. Sampling retail drug prices. Geographical coverage. Sampling over time. Factors influencing retail price observations. Determinants of drug markets. Characteristics of the retail drug markets. Products and purchases. Variables to record for each transaction. Legal issues related to data collection. Chapter 3: Principal methods of data collection in Europe. Overview of the principal methods currently in use in Europe. Covert drug purchases (by law enforcement agencies): test purchases. Objectives. Details of the method. Strengths and weaknesses. An example — National Covert Drug Purchase Database, United Kingdom. Informants run by law enforcement agencies. Objectives. Details of the method. Strengths and weaknesses. Interrogation of arrestees. Objectives. Details of the method. Strengths and weaknesses. Overt drug purchases (purchases by non-law enforcement agents). Objectives. Details of the method. Strengths and weaknesses. An example — SINTES information system, France. Surveys of drug users. Objectives. Details of the method. Strengths and weaknesses. An example — Survey ENa-CAARUD, France. An example — The Oslo study, Norway. An example — The Antenna monitoring scheme, The Netherlands. Interviews with key experts. Objectives. Details of the method. Strengths and weaknesses. An example — Project TREND, France. An example — Central Bureau of Investigation survey, Poland. Other methods. Eavesdropping. Documentation seized by law enforcement agencies. General population surveys. Ethnographic observation. Chapter 4: General data management, reporting and analysis issues. Study protocol. Products. Selecting transactions from the retail market. Dealing with non-standardised units. Data cleaning and construction of the data matrix. Construction of the data matrix. Validation procedures. Standard descriptive measures. Reporting — from local to national. Analysis at national level. Feedback to data providers. Publication. Cross-country comparative analysis. Glossary. Bibliography. Annexes. Annex 1: EMCDDA Standard Table. Annex 2: Metropolitan Police Service covert drug purchase database form. Annex 3: Notice 10-06 item 2 of the Metropolitan Police Service. Annex 4: Statistics and indicators: examples of calculation.
There are no comments for this item.